These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 37689090)

  • 1. The zebrafish for preclinical psilocybin research.
    Syed OA; Tsang B; Gerlai R
    Neurosci Biobehav Rev; 2023 Oct; 153():105381. PubMed ID: 37689090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of preclinical models in the study of psilocybin - A comprehensive review.
    Pedicini M; Cordner ZA
    Neurosci Biobehav Rev; 2023 Mar; 146():105046. PubMed ID: 36646257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
    Wulff AB; Nichols CD; Thompson SM
    Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice.
    Hesselgrave N; Troppoli TA; Wulff AB; Cole AB; Thompson SM
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33850049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards an understanding of psychedelic-induced neuroplasticity.
    Calder AE; Hasler G
    Neuropsychopharmacology; 2023 Jan; 48(1):104-112. PubMed ID: 36123427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.
    Garakani A; Alexander JL; Sumner CR; Pine JH; Gross LS; Raison CL; Aaronson ST; Baron DA
    J Psychiatr Pract; 2023 Sep; 29(5):345-353. PubMed ID: 37678363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute psilocybin enhances cognitive flexibility in rats.
    Torrado Pacheco A; Olson RJ; Garza G; Moghaddam B
    Neuropsychopharmacology; 2023 Jun; 48(7):1011-1020. PubMed ID: 36807609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders.
    Raithatha SA; Hagel JM; Matinkhoo K; Yu L; Press D; Cook SG; Sharma G; Dhananjaya D; Jensen G; Lee JB; Cai C; Gallant J; Bains J; Tucker JE; Facchini PJ
    J Med Chem; 2024 Jan; 67(2):1024-1043. PubMed ID: 37983270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms.
    Meccia J; Lopez J; Bagot RC
    Psychopharmacology (Berl); 2023 Jan; 240(1):27-40. PubMed ID: 36564671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
    Ehrmann K; Allen JJB; Moreno FA
    Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
    Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
    Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.